Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Novalent
AddedFeb 15, 2024
UpdatedJun 18, 2026
Novalent

Novalent

Series A

Novālent: Utilizing proven science to inhibit microorganism growth for up to 90 days with one application.

HQ
Greensboro, NC, US
Founded
1981
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to revolutionize antimicrobial technology, Novālent focuses on providing long-lasting protection against microorganisms. Their core product is a groundbreaking antimicrobial solution that inhibits microbial growth for up to 90 days with a single application. This product is registered with the EPA and approved for use on food contact surfaces, making it suitable for various industries, including healthcare, food service, and consumer goods.

Novālent has garnered trust from leading global brands and has demonstrated its effectiveness through extensive field trials. The company's team comprises experts in microbiology and material science, contributing to its innovative edge. Notable investors have supported Novālent's growth, enabling it to achieve significant market penetration and impact. By extending the efficacy of antimicrobial treatments, Novālent has set new standards in hygiene and public health.

Novalent - Similar Companies

Anti-Microbial Solutions logo

Anti-Microbial Solutions

Poly Group logo

Poly Group

polygroupllc.net

Zylast logo

Zylast

zylast.com

AvantGuard logo

AvantGuard

avantguardinc.com

Singletto logo

Singletto

singletto.com

Novophage logo

Novophage

novophage.com

NovoBiotic Pharmaceuticals logo

NovoBiotic Pharmaceuticals

novobiotic.com

Native Microbials logo

Native Microbials

AVnovum Therapeutics logo

AVnovum Therapeutics

Mycologics logo

Mycologics

mycologics.net

Innovative Biologics logo

Innovative Biologics

Spectrum Antimicrobials logo

Spectrum Antimicrobials

Vyv logo

Vyv

vyv.tech

Aionx Antimicrobial Technologies logo

Aionx Antimicrobial Technologies

aionx.com

ExoLytics logo

ExoLytics

exolytics.com

Novalent - Quick Facts

Who are Novalent's competitors?

Companies similar to Novalent include Anti-Microbial Solutions, Poly Group, Zylast and AvantGuard.

When was Novalent founded?

Novalent was founded in 1981.

Where is Novalent's headquarters located?

Novalent's headquarters is located in Greensboro, NC, US.

When was Novalent's last funding round?

Novalent's most recent funding round was for $11M (USD) in November 2021.

How much has Novalent raised to-date?

As of Nov 30, 2021, Novalent has raised a total of $11M (USD).

How many employees does Novalent have?

Novalent has 125 employees as of Feb 5, 2024.

Novalent - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Antimicrobial Solutions
Tags
  • Biotech
NAICS
  • 320000Manufacturing
  • 325300Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing
  • 325320Pesticide and Other Agricultural Chemical Manufacturing
  • 325000Chemical Manufacturing
SIC
  • 2870Agricultural Chemicals
  • 2879Pesticides And Agricultural Chemicals, Not Elsewhere Classified
  • 2800Chemicals And Allied Products
Show 2 more industry codes
SIC
  • 2890Miscellaneous Chemical Products
  • 2899Chemicals And Chemical Preparations, Not Elsewhere Classified